Mario Paolo Colombo

List of Publications by Year in Descending Order

278 papers	20,064 citations	73 h-index	136 g-index
313 ext. papers	22,554 ext. citations	8.1 avg, IF	6.37 L-index

#	Paper	IF	Citations
278	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020.. *Cancer Immunology, Immunotherapy*, **2022**, 1	7.4	
277	Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients. *Cancer Discovery*, **2021**,	24.4	15
276	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	
275	The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. *Molecular Oncology*, **2021**, 15, 1921-1941	7.9	9
274	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. *Cellular Immunology*, **2021**, 362, 104301	4.4	0
273	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. *Cancer Immunology, Immunotherapy*, **2021**, 70, 2429-2438	7.4	3
272	CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions. *Frontiers in Immunology*, **2021**, 12, 662048	8.4	0
271	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. *Cancer Immunology Research*, **2021**, 9, 825-837	12.5	1
270	Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer. *Cancer Research*, **2021**, 81, 4257-4274	10.1	3
269	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. *IScience*, **2021**, 24, 102510	6.1	1
268	Immune-tolerance to human iPS-derived neural progenitors xenografted into the immature cerebellum is overridden by species-specific differences in differentiation timing. *Scientific Reports*, **2021**, 11, 651	4.9	1
267	Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. *Frontiers in Immunology*, **2021**, 12, 622001	8.4	2
266	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. *Clinical Cancer Research*, **2021**, 27, 6307-6313	12.9	0
265	Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS-Istituto Nazionale dei Tumori di Milano. *Tumori*, **2020**, 300891620923790	1.7	21
264	Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models.. *Journal of Clinical Oncology*, **2020**, 38, 9547-9547	2.2	2
263	A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. *IScience*, **2020**, 23, 101562	6.1	14
262	Immunometabolic Status of COVID-19 Cancer Patients. *Physiological Reviews*, **2020**, 100, 1839-1850	47.9	9

261	Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. *EBioMedicine*, **2020**, 61, 103055	8.8	7
260	T Cell Costimulation Blockade Blunts Age-Related Heart Failure. *Circulation Research*, **2020**, 127, 1115-1117	15.7	6
259	Transcriptional Profiles and Stromal Changes Reveal Bone Marrow Adaptation to Early Breast Cancer in Association with Deregulated Circulating microRNAs. *Cancer Research*, **2020**, 80, 484-498	10.1	8
258	Infiltrating Mast Cell-Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype. *Cancer Research*, **2020**, 80, 2311-2324	10.1	7
257	Tumor-Derived Prostaglandin E2 Promotes p50 NF-B-Dependent Differentiation of Monocytic MDSCs. *Cancer Research*, **2020**, 80, 2874-2888	10.1	42
256	The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. *Oncogene*, **2019**, 38, 3636-3650	9.2	87
255	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. *Cancers*, **2019**, 11,	6.6	22
254	IL-10-producing B cells are characterized by a specific methylation signature. *European Journal of Immunology*, **2019**, 49, 1213-1225	6.1	9
253	DNA threads released by activated CD4 T lymphocytes provide autocrine costimulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 8985-8994	11.5	14
252	When Failure Is Worse Than Giving Up: The Case of CTL. *Cancer Research*, **2019**, 79, 1753-1755	10.1	
251	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. *Lung Cancer*, **2019**, 132, 72-78	5.9	34
250	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open*, **2019**, 4, e000457	6	93
249	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. *Cancer Treatment Reviews*, **2019**, 75, 39-51	14.4	85
248	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. *PLoS ONE*, **2019**, 14, e0220644	3.7	5
247	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cellular Oncology (Dordrecht)*, **2019**, 42, 815-828	7.2	9
246	SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. *Frontiers in Immunology*, **2019**, 10, 1369	8.4	30
245	Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation. *Circulation*, **2019**, 140, 2089-2107	16.7	93
244	Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2332-2332	2.2	

243	Interferon-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment. *Blood*, **2019**, 134, 1212-1212	2.2	2
242	Frontline Science: Mast cells regulate neutrophil homeostasis by influencing macrophage clearance activity. *Journal of Leukocyte Biology*, **2019**, 105, 633-644	6.5	3
241	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. *Cancer Research*, **2019**, 79, 1938-1951	10.1	33
240	A luminal EF-hand mutation in STIM1 in mice causes the clinical hallmarks of tubular aggregate myopathy. *DMM Disease Models and Mechanisms*, **2019**, 13,	4.1	8
239	Is GPNMB the Achilles Heel of Mo-MDSC While Marking Their Suppressive Activity?. *Clinical Cancer Research*, **2019**, 25, 453-454	12.9	3
238	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clinical Cancer Research*, **2019**, 25, 989-999	12.9	213
237	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. *Clinical Lung Cancer*, **2019**, 20, e413-e417	4.9	15
236	Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. *Cancer Immunology Research*, **2018**, 6, 552-565	12.5	31
235	cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. *Cell Death and Differentiation*, **2018**, 25, 2147-2164	12.7	11
234	Mast cells, basophils and eosinophils: From allergy to cancer. *Seminars in Immunology*, **2018**, 35, 29-34	10.7	43
233	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. *OncoImmunology*, **2018**, 7, e1465164	7.2	2
232	Role of PD-L1 expression in triple-negative breast cancer stem cells.. *Journal of Clinical Oncology*, **2018**, 36, 12081-12081	2.2	0
231	Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling. *Blood*, **2018**, 132, 2579-2579	2.2	
230	Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. *Cancer Research*, **2018**, 78, 5729-5730	10.1	9
229	Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. *BMC Cancer*, **2018**, 18, 899	4.8	22
228	Matricellular proteins tune myeloid-derived suppressor cell recruitment and function in breast cancer. *Journal of Leukocyte Biology*, **2017**, 102, 287-292	6.5	13
227	Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. *Cancer Immunology, Immunotherapy*, **2017**, 66, 1059-1067	7.4	23
226	Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8 T-cell Recognition of a Retroviral Antigen. *Cancer Research*, **2017**, 77, 3644-3654	10.1	36

225	Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses. *Trends in Immunology*, **2017**, 38, 648-656	14.4	47
224	Reciprocal influence of B cells and tumor macro and microenvironments in the model of colorectal cancer. *OncoImmunology*, **2017**, 6, e1336593	7.2	7
223	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. *Cancer Research*, **2017**, 77, 3685-3699	10.1	16
222	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. *Clinical Cancer Research*, **2017**, 23, 5149-5161	12.9	37
221	Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-*Molecular Cancer Therapeutics*, **2017**, 16, 365-375	6.1	7
220	On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?. *Clinical Cancer Research*, **2017**, 23, 5999-6001	12.9	9
219	Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans. *Inflammatory Bowel Diseases*, **2017**, 24, 136-148	4.5	9
218	The good and bad of targeting cancer-associated extracellular matrix. *Current Opinion in Pharmacology*, **2017**, 35, 75-82	5.1	13
217	Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. *FASEB Journal*, **2017**, 31, 5356-5370	0.9	7
216	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). *Cytokine and Growth Factor Reviews*, **2017**, 36, 1-3	17.9	0
215	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. *Frontiers in Immunology*, **2017**, 8, 1918	8.4	55
214	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nature Communications*, **2016**, 7, 12150	17.4	1388
213	Healthy and tumoral tissue resistivity in wild-type and sparc-/- animal models. *Medical and Biological Engineering and Computing*, **2016**, 54, 1949-1957	3.1	5
212	CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-B signaling. *Oncogene*, **2016**, 35, 3944-54	9.2	35
211	TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. *Clinical Cancer Research*, **2016**, 22, 3499-512	12.9	123
210	CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. *Oncotarget*, **2016**, 7, 79925-79942	3.3	22
209	Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. *Oncotarget*, **2016**, 7, 3905-20	3.3	6
208	Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells. *Blood*, **2016**, 128, 3711-3711	2.2	

207	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. *Cell Reports*, **2016**, 17, 233-248	10.6	62
206	Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. *Cancer Research*, **2015**, 75, 3760-70	10.1	19
205	Regulated Expression of miR-155 is Required for iNKT Cell Development. *Frontiers in Immunology*, **2015**, 6, 140	8.4	19
204	The ins and outs of osteopontin. *OncoImmunology*, **2015**, 4, e978711	7.2	3
203	SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. *Cancer Research*, **2015**, 75, 2387-99	10.1	28
202	CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin. *Clinical Cancer Research*, **2015**, 21, 146-56	12.9	28
201	SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. *Journal of Pathology*, **2015**, 236, 315-25	9.4	27
200	RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis. *Cancer Cell*, **2015**, 28, 253-69	24.3	121
199	The Role of Mast Cells in Molding the Tumor Microenvironment. *Cancer Microenvironment*, **2015**, 8, 167-76	6.1	46
198	Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. *Cancer Immunology Research*, **2015**, 3, 85-95	12.5	40
197	Consensus nomenclature for CD8 T cell phenotypes in cancer. *OncoImmunology*, **2015**, 4, e998538	7.2	101
196	OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.. *Journal of Clinical Oncology*, **2015**, 33, e16576-e16576	2.2	
195	MEF2C and SOCS2 in stemness regulation. *Oncoscience*, **2015**, 2, 936-7	0.8	
194	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. *Blood*, **2015**, 126, 1019-1019	2.2	
193	Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. *Growth Factors*, **2014**, 32, 41-52	1.6	16
192	Osteopontin shapes immunosuppression in the metastatic niche. *Cancer Research*, **2014**, 74, 4706-19	10.1	84
191	Mast cells control the expansion and differentiation of IL-10-competent B cells. *Journal of Immunology*, **2014**, 193, 4568-79	5.3	28
190	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. *Blood*, **2014**, 123, 1836-49	2.2	31

189	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
188	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. *OncoImmunology*, **2014**, 3, e28989	7.2	27
187	Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. *Cancer Discovery*, **2014**, 4, 110-29	24.4	78
186	Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. *Neoplasia*, **2014**, 16, 1047-58	6.4	61
185	CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. *Journal of Bone and Mineral Research*, **2014**, 29, 1295-309	6.3	28
184	Editors' Viewpoint: Response. *Cancer Research*, **2014**, 74, 635-635	10.1	
183	Mast Cells and Immune Response in Cancer **2014**, 77-98		
182	The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. *International Journal of Cancer*, **2013**, 133, 879-92	7.5	44
181	IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. *Cell Reports*, **2013**, 4, 1235-49	10.6	53
180	Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer. *Cancer Immunology, Immunotherapy*, **2013**, 62, 1811-9	7.4	2
179	Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. *International Journal of Cancer*, **2013**, 133, 383-93	7.5	16
178	Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. *Cancer Research*, **2013**, 73, 235-45	10.1	98
177	Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. *Frontiers in Immunology*, **2013**, 4, 247	8.4	20
176	Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity. *Cell Death and Disease*, **2013**, 4, e920	9.8	34
175	Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. *PLoS ONE*, **2013**, 8, e56761	3.7	38
174	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. *Blood*, **2012**, 120, 3541-54	2.2	36
173	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. *Blood*, **2012**, 120, 3007-18	2.2	265
172	Modulation of FcεRI-dependent mast cell response by OX40L via Fyn, PI3K, and RhoA. *Journal of Allergy and Clinical Immunology*, **2012**, 130, 751-760.e2	11.5	19

171	Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients. *Antiviral Therapy*, **2012**, 17, 111-8	1.6	8
170	Mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. *International Journal of Molecular Sciences*, **2012**, 13, 15107-25	6.3	28
169	The dark side of mast cell-targeted therapy in prostate cancer. *Cancer Research*, **2012**, 72, 831-5	10.1	43
168	The aryl hydrocarbon receptor modulates acute and late mast cell responses. *Journal of Immunology*, **2012**, 189, 120-7	5.3	58
167	Microenvironment-centred dynamics in aggressive B-cell lymphomas. *Advances in Hematology*, **2012** , 2012, 138079	1.5	15
166	SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. *American Journal of Pathology*, **2011**, 179, 3000-10	5.8	46
165	The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. *Journal of Autoimmunity*, **2011**, 37, 300-10	15.5	22
164	Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. *Pigment Cell and Melanoma Research*, **2011**, 24, 953-65	4.5	35
163	Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. *Oncogene*, **2011**, 30, 757-69	9.2	57
162	Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient Kit W-sh/W-sh mice. *Laboratory Investigation*, **2011**, 91, 627-41	5.9	57
161	Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. *European Journal of Immunology*, **2011**, 41, 3615-26	6.1	32
160	The bone marrow stroma in hematological neoplasms--a guilty bystander. *Nature Reviews Clinical Oncology*, **2011**, 8, 456-66	19.4	37
159	Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. *Cancer Research*, **2011**, 71, 5987-97	10.1	101
158	Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. *Cancer Research*, **2010**, 70, 7764-75	10.1	27
157	Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. *Cancer Research*, **2010**, 70, 9062-72	10.1	114
156	Xg expression in Ewing© sarcoma is of prognostic value and contributes to tumor invasiveness. *Cancer Research*, **2010**, 70, 3730-8	10.1	18
155	Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. *Journal of Experimental Medicine*, **2010**, 207, 2931-42	16.6	149
154	Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. *American Journal of Pathology*, **2010**, 177, 792-802	5.8	73

153	Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. *Cancer and Metastasis Reviews*, **2010**, 29, 295-307	9.6	173
152	Peripheral regulatory T cells and serum transforming growth factor- relationship with clinical response to infliximab in Crohn disease. *Inflammatory Bowel Diseases*, **2010**, 16, 1891-7	4.5	35
151	A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. *European Journal of Immunology*, **2010**, 40, 2902-13	6.1	52
150	CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. *Journal of Clinical Investigation*, **2010**, 120, 668-80	15.9	108
149	Polyps wrap mast cells and Treg within tumorigenic tentacles. *Cancer Research*, **2009**, 69, 5619-22	10.1	17
148	An unusual BRCA2 allele carrying two splice site mutations. *Annals of Oncology*, **2009**, 20, 1143-4	10.3	7
147	Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. *Blood*, **2009**, 114, 2639-48	2.2	158
146	CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. *Immunity*, **2008**, 29, 771-81	32.3	290
145	Matricellular proteins at the crossroad of inflammation and cancer. *Cancer Letters*, **2008**, 267, 245-53	9.9	31
144	The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. *Cancer Research*, **2008**, 68, 2745-54	10.1	321
143	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. *Journal of Experimental Medicine*, **2008**, 205, 657-67	16.6	20
142	Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. *Cancer Research*, **2008**, 68, 9050-9	10.1	146
141	OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. *Journal of Experimental Medicine*, **2008**, 205, 825-39	16.6	315
140	Regulatory T Cells in Cancer **2008**, 41-67		
139	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimuriumimmunity. *Journal of Cell Biology*, **2008**, 180, i17-i17	7.3	
138	Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. *Nature Reviews Cancer*, **2007**, 7, 880-7	31.3	313
137	The terminology issue for myeloid-derived suppressor cells. *Cancer Research*, **2007**, 67, 425; author reply 426	10.1	519
136	Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. *Annals of Oncology*, **2007**, 18, 226-32	10.3	215

135	Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. *Cancer Research*, **2007**, 67, 7675-85	10.1	73
134	Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. *Cancer Research*, **2007**, 67, 11438-46	10.1	273
133	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. *Blood*, **2007**, 109, 2871-7	2.2	293
132	Triggering CD40 on endothelial cells contributes to tumor growth. *Journal of Experimental Medicine* , **2006**, 203, 2441-50	16.6	67
131	CD99 acts as an oncosuppressor in osteosarcoma. *Molecular Biology of the Cell*, **2006**, 17, 1910-21	3.5	50
130	CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. *Journal of Immunology*, **2006**, 176, 1750-8	5.3	91
129	Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. *Cancer Research*, **2006**, 66, 2442-50	10.1	110
128	Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. *Cancer Research*, **2006**, 66, 4488-95	10.1	213
127	p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. *Cancer Research*, **2006**, 66, 11432-40	10.1	339
126	Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. *Stem Cells*, **2006**, 24, 454-61	5.8	111
125	Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. *Journal of Clinical Investigation*, **2006**, 116, 2777-90	15.9	637
124	Cancer immunotherapy based on killing of Salmonella-infected tumor cells. *Cancer Research*, **2005**, 65, 3920-7	10.1	125
123	Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. *Blood*, **2005**, 105, 2845-51	2.2	324
122	Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. *Blood*, **2005**, 106, 3846-53	2.2	89
121	In Ewing© sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. *Oncogene*, **2005**, 24, 4349-61	9.2	83
120	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. *Experimental Hematology*, **2005**, 33, 1521-30	3.1	27
119	CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell-produced IL-2. *European Journal of Immunology*, **2005**, 35, 557-67	6.1	96
118	Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. *Cancer Research*, **2005**, 65, 7942-9	10.1	39

117	Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. *Cancer Research*, **2005**, 65, 9113-6	10.1	84
116	Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. *Cancer Research*, **2005**, 65, 3437-46	10.1	435
115	Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. *Journal of Cell Science*, **2005**, 118, 3685-94	5.3	49
114	Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. *Cancer Research*, **2005**, 65, 2321-9	10.1	21
113	Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 4185-90	11.5	253
112	IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. *Journal of Immunology*, **2004**, 172, 1540-7	5.3	136
111	Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. *Journal of Immunology*, **2004**, 172, 4026-36	5.3	33
110	Role of PLZF in melanoma progression. *Oncogene*, **2004**, 23, 4567-76	9.2	60
109	Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing sarcoma cells: actin and zyxin as key intracellular mediators. *Oncogene*, **2004**, 23, 5664-74	9.2	98
108	Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis. *Cancer Immunology, Immunotherapy*, **2004**, 53, 600-8	7.4	20
107	CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. *Cancer Immunology, Immunotherapy*, **2004**, 53, 697-704	7.4	6
106	Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. *Cancer Research*, **2004**, 64, 1502-8	10.1	57
105	IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. *Journal of Immunology*, **2003**, 170, 270-8	5.3	400
104	Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. *Blood*, **2003**, 101, 568-75	2.2	22
103	Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. *Blood*, **2003**, 102, 2138-45	2.2	246
102	HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1 and USF-1. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **2003**, 1626, 1-9		17
101	Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. *Journal of Experimental Medicine*, **2003**, 198, 1475-85	16.6	116
100	OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. *Journal of Immunology*, **2003**, 170, 99-106	5.3	63

99	Lipopolysaccharide or whole bacteria block the conversion of inflammatory monocytes into dendritic cells in vivo. *Journal of Experimental Medicine*, **2003**, 198, 1253-63	16.6	97
98	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. *Journal of Clinical Investigation*, **2003**, 111, 1161-70	15.9	26
97	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. *Journal of Clinical Investigation*, **2003**, 111, 1161-1170	15.9	93
96	Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. *Cancer Genetics and Cytogenetics*, **2002**, 139, 126-32		7
95	IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. *European Journal of Immunology*, **2002**, 32, 1914-23	6.1	39
94	Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. *Cancer Immunology, Immunotherapy*, **2002**, 51, 9-14	7.4	35
93	Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. *Journal of Immunology*, **2002**, 169, 151-8	5.3	32
92	Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. *Journal of Experimental Medicine*, **2002**, 196, 541-9	16.6	296
91	Interleukin-12 in anti-tumor immunity and immunotherapy. *Cytokine and Growth Factor Reviews*, **2002**, 13, 155-68	17.9	546
90	Introduction: Cytokines and Cancer. *Cytokine and Growth Factor Reviews*, **2002**, 13, 93-94	17.9	4
89	Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. *Cancer Research*, **2002**, 62, 4390-7	10.1	21
88	The intriguing role of polymorphonuclear neutrophils in antitumor reactions. *Blood*, **2001**, 97, 339-45	2.2	345
87	Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. *Cancer Immunology, Immunotherapy*, **2001**, 50, 199-211	7.4	12
86	Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases. *European Journal of Immunology*, **2001**, 31, 3101-10	6.1	17
85	IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. *Journal of Immunology*, **2001**, 166, 3890-9	5.3	132
84	Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. *Journal of Experimental Medicine*, **2001**, 194, 1195-205	16.6	203
83	Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. *Journal of Neurosurgery*, **2000**, 92, 419-27	3.2	53
82	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. *Journal of Cellular Physiology*, **2000**, 185, 317-23	7	25

81	Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen. *European Journal of Immunology*, **2000**, 30, 768-77	6.1	27
80	Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. *Blood*, **2000**, 96, 1125-1129	2.2	123
79	DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. *Journal of Immunology*, **2000**, 165, 5133-42	5.3	290
78	Immunizing potential of cytokine-transduced tumor cells. *Methods in Molecular Medicine*, **2000**, 35, 3-26		
77	Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. *Blood*, **2000**, 96, 1125-1129	2.2	2
76	The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 8489-92	11.5	180
75	Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. *Human Gene Therapy*, **1999**, 10, 2907-16	4.8	52
74	Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. *Journal of Experimental Medicine*, **1999**, 190, 125-33	16.6	155
73	DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice. *Cancer Gene Therapy*, **1999**, 6, 349-57	5.4	14
72	Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. *Gene Therapy*, **1999**, 6, 865-72	4	18
71	Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. *Oncogene*, **1999**, 18, 1993-2001	9.2	51
70	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. *Cancer Immunology, Immunotherapy*, **1999**, 48, 132-8	7.4	8
69	Salmonella vaccine carrier strains: effective delivery system to trigger anti-tumor immunity by oral route. *European Journal of Immunology*, **1999**, 29, 693-9	6.1	50
68	Interleukin-12 as an adjuvant for cancer immunotherapy. *Methods*, **1999**, 19, 114-20	4.6	53
67	Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. *Journal of Pathology*, **1998**, 186, 390-7	9.4	11
66	Tumor and dendritic cells as cellular vaccines: confrontation and perspectives--a symposium in writing. *Cancer Immunology, Immunotherapy*, **1998**, 46, 69	7.4	1
65	HIV/gp120 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas-L upregulation. *FEBS Letters*, **1998**, 436, 461-5	3.8	11
64	Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. *Oncogene*, **1998**, 16, 3283-9	9.2	73

63	Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor. *Journal of Experimental Medicine*, **1998**, 188, 133-43	16.6	48
62	Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. *Journal of Experimental Medicine*, **1998**, 188, 589-96	16.6	252
61	Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With Salmonellatyphimurium, Results in Protective Immunity Against a Murine Fibrosarcoma. *Blood*, **1998**, 92, 3172-3176	2.2	156
60	Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With Salmonellatyphimurium, Results in Protective Immunity Against a Murine Fibrosarcoma. *Blood*, **1998**, 92, 3172-3176	2.2	31
59	Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. *Journal of the National Cancer Institute*, **1997**, 89, 1049-58	9.7	151
58	Cytokine gene transduction in the immunotherapy of cancer. *Advances in Pharmacology*, **1997**, 40, 259-307	3.7	36
57	Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. *Human Gene Therapy*, **1997**, 8, 1345-53	4.8	59
56	Apoptosis induced by HIV-gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering. *FEBS Letters*, **1997**, 411, 87-92	3.8	11
55	Differential Susceptibility to HIV-GP120Sensitized Apoptosis in CD4+ T-Cell Clones With Different T-Helper Phenotypes: Role of CD95/CD95L Interactions. *Blood*, **1997**, 89, 558-569	2.2	45
54	Immunotherapy. I: Cytokine gene transfer strategies. *Cancer and Metastasis Reviews*, **1997**, 16, 421-32	9.6	21
53	Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. *Cancer Immunology, Immunotherapy*, **1997**, 44, 197-203	7.4	61
52	Cytokines, tumour-cell death and immunogenicity: a question of choice. *Trends in Immunology*, **1997** , 18, 32-6		149
51	The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. *European Journal of Immunology*, **1997**, 27, 1570-5	6.1	47
50	Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. *European Journal of Immunology*, **1997**, 27, 2375-82	6.1	41
49	B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. *International Journal of Cancer*, **1996**, 67, 769-76	7.5	26
48	IL-1alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. *International Journal of Cancer*, **1996**, 67, 856-63	7.5	33
47	Immunotherapy I: Cyclosine gene transfer strategies. *Cancer and Metastasis Reviews*, **1996**, 15, 317-28	9.6	18
46	Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. *Journal of Experimental Medicine*, **1996**, 183, 317-22	16.6	476

45	Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. *Human Gene Therapy*, **1996**, 7, 1955-63	4.8	71
44	Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?. *Cancer Immunology, Immunotherapy*, **1995**, 41, 265-70	7.4	18
43	Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. *British Journal of Cancer*, **1995**, 72, 1224-9	8.7	40
42	IL-12 inhibits apoptosis induced in a human Th1 clone by gp120/CD4 cross-linking and CD3/TCR activation or by IL-2 deprivation. *Cellular Immunology*, **1995**, 161, 14-21	4.4	54
41	A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. *Human Gene Therapy*, **1995**, 6, 1427-36	4.8	12
40	CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. *European Journal of Immunology*, **1995**, 25, 137-46	6.1	113
39	A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. *European Journal of Immunology*, **1995**, 25, 2737-42	6.1	44
38	An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. *International Journal of Cancer*, **1995**, 62, 572-8	7.5	26
37	Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials? **1995**, 41, 265		1
36	Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. *Human Gene Therapy*, **1994**, 5, 1139-50	4.8	42
35	Refined localization of H7 and Ctt1 on distal mouse chromosome 9. *Immunogenetics*, **1994**, 40, 79-81	3.2	2
34	Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. *International Journal of Cancer*, **1994**, 56, 853-7	7.5	203
33	Expression of a growth arrest specific gene (gas-6) during liver regeneration: molecular mechanisms and signalling pathways. *Journal of Cellular Physiology*, **1994**, 158, 263-9	7	5
32	Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?. *Trends in Immunology*, **1994**, 15, 48-51		242
31	Sequence of human GAS3/PMP22 full-length cDNA. *Gene*, **1993**, 126, 289-90	3.8	10
30	Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. *Journal of Experimental Medicine*, **1993**, 178, 151-61	16.6	159
29	Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. *Journal of Immunotherapy*, **1993**, 14, 253-7	5	22
28	In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. *International Journal of Cancer*, **1993**, 54, 8-15	7.5	61

27	Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1). *Immunogenetics*, **1993**, 38, 157-60	3.2	6
26	Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA. *FEBS Letters*, **1993**, 335, 114-8	3.8	8
25	Isolation and mapping to 17p12-13 of the human homologous of the murine growth arrest specific Gas-3 gene. *Human Molecular Genetics*, **1992**, 1, 331-4	5.6	11
24	Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. *Melanoma Research*, **1992**, 2, 181-9	3.3	81
23	Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. *Human Pathology*, **1992**, 23, 1326-31	3.7	28
22	Localization of growth arrest-specific genes on mouse chromosomes 1, 7, 8, 11, 13, and 16. *Mammalian Genome*, **1992**, 2, 130-4	3.2	32
21	Expression of a growth arrest specific gene (gas-1) in transformed cells. *British Journal of Cancer*, **1992**, 66, 27-31	8.7	4
20	Cytokine gene transfer in tumor cells as an approach to antitumor therapy. *International Journal of Clinical and Laboratory Research*, **1992**, 21, 278-82		4
19	Multiple molecular alterations in mouse lung tumors. *Molecular Carcinogenesis*, **1992**, 5, 155-60	5	55
18	Tumor-cell-targeted cytokine gene therapy. *Trends in Immunology*, **1991**, 12, 249-50		5
17	The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. *International Journal of Cancer*, **1991**, 47, 746-54	7.5	45
16	Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts. *European Journal of Cancer & Clinical Oncology*, **1991**, 27, 58-62		10
15	Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. *Journal of Experimental Medicine*, **1991**, 173, 889-97	16.6	269
14	Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. *International Journal of Cancer*, **1990**, 46, 727-32	7.5	52
13	Effect of adrenergic and Ca2+ antagonists on increased ornithine decarboxylase expression in regenerating rat liver. *Biochemical Pharmacology*, **1990**, 40, 1605-13	6	10
12	A TaqI RFLP at the gas-2 locus. *Nucleic Acids Research*, **1989**, 17, 7545	20.1	
11	Ava I RFLP at the gas-1 locus on mouse chromosome 12. *Nucleic Acids Research*, **1989**, 17, 5415	20.1	3
10	Strain polymorphism and tentative mapping of mouse ornithine decarboxylase. *Nucleic Acids Research*, **1988**, 16, 9075	20.1	1

9	Inheritance of a mutant histocompatibility gene and a new mammary tumor virus genome in the B6.KH-84 mouse strain. *Immunogenetics*, **1987**, 26, 99-104	3.2	7
8	Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1987**, 907, 163-74	11.2	2
7	Control of human melanoma growth in nude mice by autologous allo-activated peripheral blood lymphocytes. *International Journal of Cancer*, **1986**, 38, 923-7	7.5	1
6	Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studies. *Research in Clinic and Laboratory*, **1986**, 16, 1-20		5
5	Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host non-T cells. *Cancer Immunology, Immunotherapy*, **1985**, 20, 198-204	7.4	10
4	Genetic Unresponsiveness to a Murine Fibrosarcoma Determined by the Host Genetic Environment but not by Lymphocyte Precursor Genotype. *Tumori*, **1985**, 71, 91-96	1.7	
3	Passive adoptive immunotherapy of low-immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes. *International Journal of Cancer*, **1984**, 34, 807-13	7.5	12
2	In vitro detection of cell-mediated immunity to individual tumor-specific antigens of chemically induced BALB/c fibrosarcomas. *International Journal of Cancer*, **1983**, 31, 483-9	7.5	21
1	Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice. *International Journal of Cancer*, **1982**, 29, 323-32	7.5	25